Review

Vitamins in Alzheimer’s Disease—Review of the Latest Reports

Anita Mielech†, Anna Puścion-Jakubik *†, Renata Markiewicz-Żukowska and Katarzyna Socha

Department of Bromatology, Faculty of Pharmacy with the Division of Laboratory Medicine, Medical University of Białystok, Mickiewicza 2D Street, 15-222 Białystok, Poland; an.mielech@gmail.com (A.M.); renmar@poczta.onet.pl (R.M.-Z.); katarzyna.socha@umb.edu.pl (K.S.)

* Correspondence: anna.puscion-jakubik@umb.edu.pl; Tel.: +48-8574-854-69
† These authors contributed equally to this work.

Received: 3 November 2020; Accepted: 9 November 2020; Published: 11 November 2020

Abstract: Alzheimer’s disease (AD) is the most common form of dementia, and the aging of the population means that the number of cases is successively increasing. The cause of the disease has not been established, but it is suggested that many factors affect it, including nutritional aspects. Part of the work, the PubMed database has been searched, beginning from 2005, for terms related to key nutritional aspects. A diet rich in antioxidant vitamins can improve the cognitive functions of patients. Thanks to an adequate intake of B vitamins, homocysteine levels are reduced, which indirectly protects against the development of the disease. A properly balanced diet, as well as the use of appropriate supplementation, can contribute to improving the clinical condition of patients with AD.

Keywords: Alzheimer disease; nutrition; antioxidant

1. Introduction

Alzheimer’s disease (AD) is one of the most common forms of dementia in the world, accounting for 2/3 of all dementias. In aging societies, the number of AD patients is predicted to increase. For example, in 2005 in Poland there were 5.9 million people over 60, and according to estimates, by 2030 this number will have increased to over 9 million [1,2]. In 2050, the disease will have affected about 115 million people worldwide [3].

The cause of AD is still unknown, but there are several hypotheses that attempt to explain the etiology of the disease. Usually, the cause is multifactorial. The gold standard in diagnosis is the accumulation of β-amyloid plaques inside the cerebral cortex and the presence of tangles of intra-nerve filamentous neurons containing tau proteins, as well as amyloid angiopathy [4]. The role of microRNA (miRNA) in neuronal cell death that is induced by β amyloid is emphasized [5]. About 95% of the cases begin at the age of 60–65 [4].

In AD, memory disorders and progressive cognitive dysfunctions occur, such as speech disorders, impairment of visual-spatial skills, and behavioral disorders [6,7]. Many symptoms, such as sleep disturbances and deterioration of mood and anxiety are revealed before clinical diagnosis of dementia. Symptoms such as confusion, aggressive behavior, and delusions may remain undiagnosed for a long time [8]. In AD, apart from the classic amnestic form, other forms are distinguished, with predominant language disorders (referred to as the speech or language variant), the visual variant, the variant with behavior disorders (frontal variant), and the form with apraxia (apractic variant) (Table 1) [9].
Table 1. Characteristics of symptoms of different variants of Alzheimer’s disease [9].

| Language Variant/Logopenic Progressive Aphasia (LPA) | Frontal Variant | Visual Variant/Posterior Cortical Atrophy (PCA) | Apraxic Variant |
|-------------------------------------------------------|-----------------|-----------------------------------------------|-----------------|
| For at least the first two years, there is only an isolated language deficit of unnoticeable onset, progressive, without previous language disorders, and no other specific causes for the above disturbances. | Pronounced disturbances in behavior and executive functions. These often mimic the behavioral disturbances in frontotemporal dementia. | Initially, visual-spatial disorders dominate without any evident ophthalmic pathology, later psychotic symptoms appear, and in the final stage, there is a dementia syndrome with deep cognitive deficits, disturbing everyday functioning. | Inability or difficulty in performing learned movements, while understanding the command, the willingness to perform it. The lack of impaired motor coordination, and weakened sensation and muscle strength. |
| After two years, other cognitive functions deteriorate, although the language deficit dominates and deepens much faster than the other ones. | This is followed by the inability to see more than one object or one element of an object at the same time (simultaneous diagnosis), finger agnosia, page orientation disorders (right/left), and apraxia. | |

Currently, AD therapy uses drugs from the group of acetylcholinesterase inhibitors, such as rivastigmine and donepezil, slowing down the breakdown of acetylcholine, as well as memantine, an N-methyl-D-aspartate receptor (NMDA receptor) antagonist, whose task is to block glutamate receptors. Memantine is recommended for moderate and severe patients. Unfortunately, none of the current pharmacological treatments can stop the disease, but only decelerate its progression [10].

There are reports of common pathophysiology of two amyloidoses, AD and type 2 diabetes. In both conditions, insulin resistance, carbohydrate disorders, systemic oxidative stress, inflammation, amyloid accumulation, and cognitive decline occur. These features may indicate a common basis for these diseases. AD with concomitant type 2 diabetes is associated with so-called brain insulin resistance, which may increase the additional pathophysiological mechanisms of AD. The onset of type 2 diabetes increases the risk of AD by 50 to 100%, which is why a well-balanced diet can delay this process [11].

Optimal supply of adequate nutrients (e.g., by introducing a Mediterranean diet) or increased consumption of selected ingredients (for example, a ketogenic diet) [12], as well as avoiding toxic elements, are essential for the proper functioning of the brain and, consequently, the prevention of neurodegenerative diseases. Therefore, this publication reviews the latest literature on supporting AD therapy by taking vitamins, mainly with antioxidant properties.

2. Materials and Methods

This publication reviewed research on the importance of nutrition in AD, published from 2005 to 2020. Only human models were included in the review, with a minimum of 100 participants. In the case of several basic research papers and textbooks, reference was made to the older studies. The PubMed publication database searched for “Alzheimer’s disease”, “cognitive impairment”, “diet”, “vitamins”, “intake”, “level in serum”. The full texts of selected papers were analyzed in order to assess whether they met the adopted criteria. The publications available in a language other than English were excluded. This review presents the most important publications describing the state of the art regarding vitamin intake in AD.
3. Results and Discussion

3.1. B Vitamins

Vitamins B are a diverse group in terms of structure and function. Folates, which provide methyl groups necessary for DNA methylation, play an important role in the pathogenesis of neurological diseases [13]. The beneficial effect of vitamin B on cognitive function is associated with the metabolism of homocysteine, which contributes to increased cardiovascular risk and increased cognitive impairment [14]. In patients with AD, there is a decrease in DNA methylation. Nutrition can affect the regulation of gene expression and, thus, indirectly, can have an impact on the course of the disease. These vitamins are substances closely related to the methionine cycle [7]. Vitamin B12 is involved in the transformation of homocysteine to methionine, and vitamin B6 and folic acid are cofactors for this reaction. The deficiency of the above vitamins causes accumulation of homocysteine in the body [15]. This reduces the concentration of S-adenosylmethionine, which is a methyl donor. DNA demethylation is induced, which increases the overexpression of genes associated with the occurrence of AD [7].

Table 2 contains data on the intervention and measurement of B vitamins in AD patients.

Table 2: Summary of studies on vitamin B intake and measurements in AD.

| Vitamins | Type of Study | Number of Participants/Age [Year] | Assessment | Intervention/Measurements | Duration | Results | References |
|----------|--------------|----------------------------------|------------|--------------------------|----------|---------|------------|
| **INTERVENTIONS** | | | | | | | |
| Vitamins B | randomized controlled trial | 266/≥70 | MMSE, Hopkins Verbal Learning Test, CVLT | 0.8 mg folic acid + 20 mg vitamin B6 + 0.5 mg vitamin B12/day | 2 years | (+) slowing cognitive decline | [16] |
| Folic acid | randomized controlled trial | 121/40-90 | MMSE, ADL | 1.25 mg of folic acid + doneperil/day 500 µg methylcobalamin + 400 µg folic acid or placebo/day | 6 months | (+) beneficial effects in patients with AD | [17] |
| Vitamins B | randomized placebo controlled trial | 279/≥65 | MMSE, NTB, CDR | 400 µg of folic acid + 500 µg of vitamin B12/day | 2 years | (-) lack of reduction of cognitive decline | [18] |
| Vitamin B12, folic acid | randomized, placebo-controlled trial | 2919/74.1 ± 6.5 | MMSE and others tests | | 2 years | (-) lack of reduction of cognitive decline | [19] |
| **MEASUREMENTS** | | | | | | | |
| Folic acid, vitamins B6 and B12 | randomized trial | 266/≥70 | CDR | folic acid, vitamins B6 and B12 measurements in serum | 2 years | (+) the effectiveness of vitamin B therapy when omega-3 levels are in the upper normal range (+) high folate and B12 levels are protective factors (-) serum folic and vitamin B12 levels are not reliable tests for screening presymptomatic AD | [20] |
| Vitamin B12 | cross-sectional study | 4605 (2396 with AD)/≥55 | China’s validation MMSE | homocysteine and B12 serum levels | 1 measurement | | [21] |
| Vitamin B12 and folic acid | cross-sectional study | 290/geriatric patients | MMSE and others tests | vitamin B12 and folic acid level | 1 measurement | | [22] |
| **CONSUMPTION** | | | | | | | |
| Vitamins B | cohort study | 2533/50-70 | - | diet intake of vitamin B12, B6 | 2.3 years | (-) low intake of vitamin B12 intensity cognitive decline | [23] |

(+)—confirmed or (−)—no confirmed association of intervention/concentration measurement/consumption with Alzheimer’s disease; ADL, Activities of Daily Living scale; CDR, Clinical Dementia Rating scale; CVLT, California Verbal Learning Test; MMSE, Mini-Mental State Examination; NTB, Neurocognitive test Battery; TICS-M, The Modified Telephone Interview for Cognitive Status.

The effect of B group vitamins (folic acid, pyridoxine and cobalamin) on homocysteine levels was confirmed in 266 participants over 70 years of age with mild cognitive impairment (MCI). Half of the participants (n = 133) were in the placebo group. The following supplementation was used: 0.8 mg folic acid, 20 mg vitamin B6, and 0.5 mg vitamin B12 for 2 years. As a result of therapy with
group B vitamins, homocysteine concentration in the supplemented group was 30% lower compared to the placebo group. It was noted that patients undergoing supplementation (initial methionine concentration above 11.3 µmol/L) achieved better results in the Mini-Mental State Examination (MMSE) test, episodic memory, and semantic memory [16].

In a randomized study conducted in newly diagnosed AD patients over 60 years of age (n = 121), the effect of supplementation with folic acid on the inflammatory process and on cognition was assessed. Patients used donepezil, and for half a year they were additionally supplemented with folic acid at a dose of 1.25 mg/day. Supplemented patients obtained statistically higher results in the MMSE test compared to the control group, which did not receive folic acid. The authors emphasize that inflammation may play an important role in the interaction between AD and folic acid [17].

Different effects were noticed in other studies, where supplementation with vitamin B12 and folic acid did not reduce the development of cognitive disorders in elderly people with elevated levels of homocysteine; homocysteine concentration after 24 months of supplementation (9.3 ± 2.4 µmol/L), folate (48.0 ± 12.6 nmol/L), and active vitamin B12 (123.6 ± 13.6 pmol/L) [18].

A multicenter, double-blind study involving 2919 patients over 65 years of age, studied the effects of ingestion of 400 µg of folic acid and 500 µg of vitamin B12. The placebo and study group received an additional 15 µg of vitamin D3. The authors did not show a beneficial effect on cognitive skills. However, they emphasized that the above supplementation might slow down cognitive impairment [19].

In the study conducted by Oulhaj et al. [20], 266 participants with mild cognitive impairment were divided into a supplement group (folic acid, vitamin B6 and B12) for 2 years and a placebo group. It was shown that treatment with group B vitamins did not slow down the cognitive dysfunctions when the concentration of omega-3 fatty acids was low, whereas when the concentration was above 579 µmol/L, these vitamins inhibited the development of dementia processes, which was confirmed by Hopkins Verbal Learning Test-Revised (HVLT-DR) longitudinal scores of episodic memory. Treatment with vitamin B caused a decrease in total homocysteine levels, which resulted in a reduction in the rate of gray matter atrophy.

A cross-sectional study conducted by Meng et al. [21] on 4605 participants demonstrated that higher serum homocysteine levels were associated with an increased risk of AD. High levels of folic acid and vitamin B12 were factors protecting against cognitive impairment [21].

Ulusu et al. [22] attempted to use the determination of vitamin B12 and folic acid in a group of 290 patients as a marker of dementia. This study needs to be reconducted on a larger number of patients because a classification error was made: 5 patients had normal serum folate levels and the reference range was 4.6 to 18.7 ng/mL.

A cohort study by An et al., published in 2019 [23] involving 2533 participants with dementia or normal cognitive function, found that insufficient vitamin B12 intake contributed to cognitive decline, and adequate levels of folic acid, vitamin B6, and vitamin B12 had a beneficial effect on the cognitive resources of participants without cognitive impairment.

In summary, the effect of nutritional intervention in the form of dietary supplementation with vitamins B seems to be inconclusive, as shown by the analysis of individual publications. While it has been indicated that the measurement of serum folate and vitamin B12 levels is not a reliable test, it is suggested that high serum levels of vitamin B12 may be a protective factor.

Recommendations for the consumption of vitamin B for adults have been set at the level of the estimated average requirement (EAR) for B1, 1.1 and 1.3 mg of thiamine (for men and women, respectively); for B2, 1.1 and 0.9 mg of riboflavin; for B3, 12 and 11 mg niacin equivalent; for B6, 1.4 and 1.3 mg of vitamin B6, 320 µg of folate equivalent and 2 µg of cobalamin for both gender [24].

3.2. Antioxidant Vitamins

Increased oxidative stress is one of the factors contributing to the onset and advancement of neurodegenerative processes. Impaired antioxidant processes, excessive free radical accumulation,
and age-related oxidative stress of brain tissue and lymphocytes are noted [25]. Pleiotropic mechanism of antioxidants, manifested, e.g., in a reduction of oxidized lipid membranes, reduction of nucleic acid damage or prevention of carbonylation of proteins, prevents the identification of a damaged specific pathway that is responsible for the formation of AD [26].

In a 2014 meta-analysis, levels of vitamins, microelements, and fatty acids in the blood were assessed in patients with AD and in a group of elderly people without cognitive impairment. Statistically significant vitamin deficiencies were found in A (9 tests), C (8 tests), E (20 tests), folates (31 tests), and vitamin B12 (32 tests) in the group of patients with AD, which indicates the need to provide the correct amounts of the above ingredients in diet or, in the absence of such a possibility, through supplementation. It was emphasized that AD patients have impaired systemic availability of the studied nutrients [27].

### 3.2.1. Vitamin A

A characteristic feature of inflammation of the nervous system is microglial activation. Inflammation occurs in chronic and acute neuropsychiatric diseases. Literature data indicates that microglia activation is known to be one of the causes of AD. Moreover, malfunctioning of the microglia may result in changes in local concentrations of retinoic acid [28]. In addition, vitamin A and its derivatives play an important role in the differentiation of nerve cells, as well as in the expression of neurotransmitters in the brain and gene expression through interaction with retinoic acid and retinoid X receptors [29].

A literature review showed that vitamin A was the least studied of the antioxidant vitamins. Vitamin A intake or dietary intake may improve cognitive function in AD patients, as shown in Table 3.

| Vitamin | Study Design | Participants | Assessment | Intervention/Measurements | Duration | Results | References |
|---------|--------------|--------------|------------|--------------------------|----------|---------|------------|
| Vitamin A | cross-sectional study | 333/≥60 | MMSE, Dementia Rating Scale, Geriatric Depression Scale, Rey Auditory Verbal Learning | vitamin A serum level | 1 measurement | (+) deficiency increases the risk of MCI | [30] |
| β-carotene | prospective study | 49,493/average: 48 | SCF, FFQ test | long-term intakes of carotenoids | 13 years | (+) higher consumption of β-carotene is associated with a lower risk of cognitive performance | [31] |
| β-carotene | randomized double-blind, placebo-controlled study | 2533/45–60 | semantic and phonemic fluency tests, executive function | six 24-h dietary records | 13 years | (−) consumption of fruit rich in β-carotene did not decrease the risk of developing cognitive impairment | [32] |

(+)—confirmed or (−)—no confirmed association of intervention/concentration measurement/consumption with Alzheimer’s disease, FFQ, Food Frequency Questionnaire; MMSE, Mini-Mental State Examination; SCF, Subjective Cognitive Function; MCI, mild cognitive impairment.

Low dietary intake of vitamin A is associated with an increased risk of dementia, which was confirmed in the group of 333 participants [30].

A study by Yuan et al. (2020) showed that higher consumption of β-carotene reduced the risk of cognitive impairment [31]. There are also studies that do not confirm the beneficial effects of this ingredient.

In a prospective study conducted by Pèneau et al., it was shown that the consumption of fruits, which are a source of β-carotene, did not reduce the risk of cognitive dysfunction [32]. Other studies on the effects of vitamin A on AD do not meet the inclusion criteria for this article.
Moreover, vitamin A is involved in neuronal differentiation and also influences the secretion of neurotransmitters in the brain [29,33].

In conclusion, it has been shown that AD patients are deficient in vitamin A, but in the case of increased consumption of β-carotene, the assessment of its effect on cognitive abilities has failed to provide definitive evidence of benefit. For example, the vitamin A intake recommendations for the population in Poland, at the level of the EAR is 630 µg of retinol equivalent/day for men, for women: 500 µg/day [24].

3.2.2. Vitamin C and E

Vitamin E can be stored in the central nervous system, where it reduces lipid peroxidation and β-amyloid deposition. Therapy with antioxidant substances should be implemented in the earliest possible stage of the disease [34].

In patients with AD, there is a correlation between blood vitamin C and vitamin E levels and dementia [35]. Ascorbic acid has a neuroprotective effect because it has the ability to scavenge free radicals, reduces β-amyloid activity, and is also involved in the chelation of iron, zinc, and copper. It is a key antioxidant of the central nervous system [36]. In a rat study, a pro-oxidative diet has been shown to increase the level of amyloid precursor protein [37].

Table 4 summarizes the data on the effect of vitamin C and E intake or supplementation on the cognitive abilities of AD patients.

In the study conducted on 613 patients, the effects of α-tocopherol (at a dose of 2000 IU/day), memantine (20 mg/day), and combinations of these substances were assessed. The observation period was 2.27 years. Vitamin E alone proved to slow down cognitive decline in patients with mild to moderate AD. Interestingly, memantine or memantine therapy, together with α-tocopherol gave less beneficial effects [38].

The results of studies on vitamin E supplementation in patients with AD are inconclusive. In a cohort study, 7540 patients over 60 years of age were treated with long-term supplementation with vitamin E (400 IU/day), selenium (200 µg/day), and vitamin E with selenium (duration of use: 5.4 ± 1.2 years), but the therapy did not prevent dementia [39]. Similar observations were obtained in a study assessing vitamin E supplementation at a dose of 300 mg and 400 mg of vitamin C on the cognitive function of the elderly with MCI (n = 256, age: 60–75 years). The intervention lasted a year and resulted in a reduction of the oxidative stress of the body, including a decrease in the level of malonic aldehyde, but did not improve cognitive abilities [40].

Higher brain γ-tocopherol levels are associated with presynaptic protein levels in the midfrontal cortex. These results suggest that vitamin E plays a significant role in maintaining presynaptic protein levels (synaptophysin, synaptotagmin, septin 5, syntaxin, synaptosomal associated protein 25 (SNAP-25), vesicle-associated membrane protein (VAMP), complexin-I, complexin-II) [41].

Patients with mild cognitive impairment (MCI, n = 166) and people diagnosed with AD (n = 168) have been shown to have significantly lower total tocopherols (6.80 µmol/mmol cholesterol and 6.40 µmol/mmol, respectively), total tocotrienols (97.28 nM/mmol cholesterol and 91.33 nM/mmol cholesterol, respectively) and total vitamin E in the blood (6.9 µmol/mmol cholesterol and 6.49 µmol/mmol), compared to persons with normal cognitive abilities (CN, n = 187), whose total tocopherols were 7.67 µmol/mmol cholesterol, total tocotrienols—118.02 nM/mmol cholesterol, total vitamin E—7.8 µmol/mmol cholesterol [42].

In a 13-year study on a group of 2533 French people aged 45 to 60, the relationship between fruit and vegetable consumption (400 g) and cognitive ability was assessed using neuropsychological tests. It was proved that the consumption of fruit and other products rich in vitamin C and vitamin E positively correlated with the results of verbal memory test, in contrast to the consumption of vegetables and vegetables rich in β-carotene [32].

Another prospective, longitudinal cohort study (n = 9250) also confirmed the beneficial effect of fruit consumption on reducing the risk of AD [43].
Table 4. Summary of studies on vitamin C and E consumption, supplementation, and blood measurements, and AD.

| Vitamins | Study Design | Participants | Assessment | Intervention/Measurements | Duration | Results | References |
|----------|--------------|--------------|------------|---------------------------|----------|---------|------------|
|          |              | [n]/[Age]    |            |                           |          |         |            |
| E        | randomized controlled trial | 613 with AD/78.8 ± 7.1 | MMSE | 2000 IU/day of α-tocopherol + 20 mg/day of memantine | 2.27 years | (+) slowing functional decline | [38] |
| E        | randomized controlled trial cohort study | 7540 >60 | MIS, TICS-m, NYU Paragraph Delayed Recall | 400 IU of vitamin E/day and/or 200 µg of selenium/day | 6 years | (−) supplementation does not prevent AD | [39] |
| C and E  | randomized controlled trial | 256(60-75 | MMSE | 300 mg of vitamin E + 400 mg of vitamin C/day | 1 year | (−) supplementation does not prevent cognitive decline | [40] |

**MEASUREMENTS**

| E        | cross-sectional study | 113/88.5 ± 6.0 | MMSE | α- and γ-tocopherol brain levels | 3 years | (+) vitamin E facilitates maintenance a presynaptic proteins level | (+) lower levels of total tocopherols, total tocotrienols, and total vitamin E are associated with an increased likelihood of developing AD | [41] |
| E        | cross-sectional study | 716/>65 | MMSE | tocopherols and total vitamin E levels | 1 measurement |         |            |

**CONSUMPTION**

| C and E  | double-blind, placebo-controlled | 2533/45-60 | verbal memory (RI-48 cued recall, semantic, and phonemic fluency tests) and executive function (trail-making and forward and backward digit span tests) | intake of fruit and vegetable intake (24-h dietary records) | 13 years | (+) improvement of verbal memory | [32] |
| C        | prospective, longitudinal cohort study | 925/58-98 | FFQ | intake of strawberries (vitamin C) | 6.7 years | (+) possible reduction of AD | [43] |

(+)—confirmed or (−)—no confirmed association of intervention/concentration measurement/consumption with Alzheimer’s disease, FFQ, Food Frequency Questionnaire; MIS, Memory Impairment Screen; MMSE, Mini-Mental State Examination; NYU, New York University; TICS-m, modified Telephone Interview for Cognitive Status.

A review of the literature from 2012 assessing the effect of ascorbic acid intake on cognitive functions revealed ambiguous information about the effectiveness of the use of vitamin C in AD. The hypothesis was presented that the brain draws ascorbic acid from the peripheral pool to endure oxidative stress [44].

In conclusion, research results indicate that decreased vitamin E concentration may be associated with an increased risk of AD, supplementation at higher doses (2000 IU) than lower doses (400 IU) is more effective, and increased consumption of antioxidant vitamins (E and C) may help to improve cognitive abilities.

Vitamin C intake by adults should be 75 mg/day for men and 60 mg/day for women. Standards are set at the EAR level. The vitamin E intake recommendations at the level of the adequate intake (AI) is 10 µg of retinol equivalent/day for men, for women, 8 µg/day [24].

3.2.3. Vitamin D

Vitamin D also plays an important role in neurodegenerative processes. Its deficiency is a genetic risk factor for AD, Parkinson’s disease, multiple sclerosis, and vascular dementia [45].

Table 5 summarizes the research on the effects of vitamin D on the cognitive abilities of patients with AD.
Table 5. Summary of studies on vitamin D supplementation and blood measurements in AD.

| Vitamin | Study Design                          | Participants [n/Age [Year]] | Assessment | Intervention/Measurement | Duration | Results                                                                 | Reference |
|---------|---------------------------------------|------------------------------|------------|--------------------------|----------|--------------------------------------------------------------------------|-----------|
| D       | randomized double-blinded placebo-controlled trial | 4144/>65                  | WHIMS, MMSE | 1000 mg of calcium carbonate + 400 IU of vitamin D(3) | 8 years  | (−) no association between treatment and incident cognitive impairment  | [46]      |
| D       | cross-sectional study                  | 146/79.1 ± 7.0              | MMSE       | 25(OH)D serum level      | 1 measurement | (+) higher serum 25(OH)D level are associated with MMSE score           | [47]      |
| D       | cross-sectional study                  | 208/79 ± 1                  | MMSE, CDR  | serum 25-hydroxyvitamin D (25(OH)D levels) | 1 year   | (+) low vitamin D are associated with cognitive decline                 | [48]      |
| D       | randomized controlled trial            | 1154/79.7 ± 8.4             | MMSE       | serum levels of 25(OH)D  | 8 years  | (+) low levels are associated with cognitive decline                    | [49]      |
| D       | cohort study                           | 2990/76.5 ± 3.9             | MMSE-KC, Test Digit Span | 25(OH)D serum level   | 2 years  | (−) no relationship between vitamin D levels and cognition             | [50]      |
| D       | cohort study                           | 661/≥65                    | 3MS        | Plasma 25-hydroxyvitamin D | 10 years | (+) higher 25(OH)D concentrations increase risk of dementia and AD in women | [51]      |
| D       | retrospective, longitudinal cohort study| 299/61 ± 10, 66 ± 8        | MMSE       | 28 nutritional biomarkers in blood and 5 in cerebrospinal fluid, including 1,25(OH)2 | 2-5 years | (−) high vitamin D is associated with cognitive decline               | [52]      |

(+)—confirmed or (−)—no confirmed association of intervention/concentration measurement/consumption with Alzheimer’s disease, 3MS, Modified Mini-Mental State; CDR, Clinical Dementia Rating scale; MMSE, Mini-Mental State Examination; MMSE-KC, Mini-Mental State Examination in the Korean version; WHIMS, Women’s Health Initiative Memory Study.

In randomized, double-blinded placebo-controlled study on 2044 participants, supplementation of 1000 mg of calcium carbonate with 400 IU of vitamin D(3) did not improve cognitive impairment [46]. The effect of vitamin D levels on cognitive functions was studied in a group of 146 patients (78 women and 68 men). Among other things, brain imaging by magnetic resonance imaging was performed. It was shown that patients who obtained lower results in the MMSE test were characterized by lower serum vitamin D concentration [47].

Low blood levels of vitamin D may increase cognitive decline in people with dementia [48,49]. The InCHIANTI study, conducted on 858 patients over 65 years of age, showed that low serum 25-hydroxyvitamin levels were associated with an increased risk of cognitive impairment. When assessing the vitamin’s concentration in patients with a deficiency (below 25 nmol/L) and patients with normal levels (above 75 nmol/L), the relative risk of corrected cognitive decline was 1.6 [49].

In two cohort studies, no protective effect of high vitamin D levels on cognitive performance was observed [50,51].

Leeuw et al. [52] evaluated 28 nutritional biomarkers in blood and 5 in cerebrospinal fluid. It was shown that higher levels of w1.25 (OH) in serum were associated with impaired cognitive functions. Among other factors, the authors also mentioned low levels of S-adenosylmethionine and high levels of HDL, theobromine, cholesterol, and iron.

Vitamin D has the ability to reduce inflammation in the hippocampus and mitigate the accumulation of β-amyloid in the process of increased phagocytosis. This vitamin stabilizes the activity of calcium channels, regulating calcium homeostasis, disturbed by the deposition of β-amyloid. In addition, it increases the expression of vitamin D receptor, which further exerts an antioxidant effect [53]. It has been shown that vitamin D therapy in the course of AD prevents the synthesis of β-amyloid and promotes the clearance of this peptide from the brain [45]. A dose of 50,000 IU, used 3 times a week for 4 weeks, was safe and effectively normalized 25(OH) D levels in the blood serum of patients [54]. In a Annweiler et al. protocol (2011) [55], it was assumed that supplementation with 100,000 IU of
cholecalciferol with memantine for one month enhanced cognition and memory capacity in patients with moderate AD. There is evidence that high vitamin D levels improve cognition, particularly in mild AD [56].

In addition, it is suspected that the use of vitamin D together with memantine in patients with moderate forms of the disease improves cognitive performance and memory ability by reducing the loss of neurons. The neuroprotective effects of vitamin D and memantine may be potentiated [53].

Summing up, a low level of vitamin D in the serum is associated with the risk of cognitive disorders, but supplementation with a dose of 400 IU does not bring any results (elderly people are recommended several times higher doses).

For example, the vitamin D intake recommendations for the population in Poland, at the level of the AI is 15 µg of cholecalciferol/day for men and for women [24].

3.2.4. Other Factors

Recently published systematic reviews and meta-analyses show the beneficial effects of various diets, including the Mediterranean diet and the “healthy diet”, which are based, among other things, on consuming more foods that provide the vitamins discussed in this study.

There is no correlation between meat consumption and the occurrence of cognitive impairment [57].

The Mediterranean diet is characterized by high consumption of vegetables and fruits, which are exceptionally rich in water-soluble vitamins. It has been shown that the Mediterranean diet protects against the development of cognitive impairment [58], whereas a ketogenic diet may have an impact on memory functions due to its influence on neurotransmission. In a systemic review by Grammatikopoulou et al., the application of ketogenic therapy (Medium Chain Triglycerides, MCT supplementation), both long-term and interventional, improved cognitive functions [59].

The effect of “healthy diets” on cognition has also been studied. It has been reported that healthy eating patterns reduce the risk of dementia, while a high-fat diet and diets with a high glycemic index increase neuronal damage [60,61]. Proinflammatory diet also may increase the progression of dementia [62].

It has been proven that the use of nutritional formulas, fatty acids, ginseng, inositol, probiotics, and products rich in flavonoids may delay the progression of dementia [63,64]. On the other hand, according to Heider et al.’s (2020) systematic review and meta-analyses, supplementation of vitamin B, E, omega-3, and nutritional formulas does not improve cognitive function [65].

Table 6 summarizes the meta-analyses in which the impact of consumption of B vitamins, vitamins C, D, and E on the health of AD patients was assessed.

In summary, the impact of most of the vitamins on cognitive function remains ambiguous. As far as B vitamins are concerned, the reasons authors give for the inefficiency of supplementation include: the insufficient size of the group to detect differences in cognitive abilities, the load on blood vessels, and the use of other drugs (which could reduce patients’ sensitivity to supplementation), no imaging of brain lesions, which is the most sensitive and reliable method of assessing changes in the brain [18], the interaction between, among others, vitamin B12 and vitamin D, which could weaken the effect of vitamin B12 [19]; in the case of the absence of expected effects of increased intake or supplementation with vitamin A (which is a fat-soluble vitamin): increased fatty acid content in patients, possibly body fat [30]; in the case of no improvement in cognitive function after an intervention involving supplementation with vitamin E, the authors point to inappropriate group selection (e.g., only one sex), too short duration of supplementation, too low doses of vitamin [39]. As for the reasons for the lack of effectiveness of vitamin D supplementation, the authors emphasize, inter alia, taking only 1 measurement, different levels of education, and groups disparate in terms of age [48].
### Table 6. A review of meta-analyses and systematic reviews of recent years on the effects of nutrition on AD.

| Factors | Type of Analysis | Results | Year | References |
|---------|------------------|---------|------|------------|
| **VITAMINS** | | | | |
| Vitamins B6, B12, and folate | systematic review and meta-analysis: 8 cross-sectional, 13 longitudinal | No link between the concentration of vitamin B in the blood and the risk of cognitive disorders. | 2020 | [66] |
| Vitamins B | meta-analysis: 11 large studies | Lowering homocysteine levels through vitamin B supplementation does not improve cognitive function. | 2016 | [67] |
| Folic acid, vitamin B12 | meta-analysis: 68 studies | High homocysteine levels and low levels of folic acid and vitamin B12 increase the risk of AD. | 2015 | [56] |
| Vitamins C, E, and β-carotene | meta-analysis: 7 studies | Consumption of vitamins E, C, and β-carotene reduces the risk of AD. Vitamin E is the strongest predictor. | 2012 | [68] |
| Vitamin D | meta-analysis: 12 prospective cohort studies, 4 cross-sectional studies | Vitamin D deficiency increases the risk of dementia and AD. | 2019 | [69] |
| Vitamin D | meta-analysis: 6 prospective cohort studies | Serum vitamin D deficiency is associated with the risk of AD. | 2019 | [70] |
| Vitamin D | meta-analysis: 7 prospective cohort studies, 1 retrospective cohort study | Higher levels of 25(OH)D reduce the risk of AD. | 2019 | [71] |
| Vitamin E | meta-analysis: 31 observational studies and clinical trial | Lower a-tocopherol levels increase the risk of AD and MCI. | 2019 | [72] |
| Vitamin E | meta-analysis: 17 studies | Lower vitamin E levels are associated with the risk of AD. | 2018 | [73] |
| **OTHER NUTRITIONAL FACTORS** | | | | |
| Fatty acids, foods rich in polyphenols | systematic review: 10 randomized clinical trials | Fatty acids and products rich in flavonoid are a protective factor in the development of dementia | 2020 | [64] |
| Ketogenic diet | systematic review: 10 randomized clinical trials | MCT and other ketogenic therapies improve cognition | 2020 | [59] |
| Meat consumption | systematic review and meta-analysis (PRISMA): 10 studies | No association between meat consumption and cognitive impairment | 2020 | [57] |
| Mediterranean diet | systematic review: 7 randomized clinical trials, 38 longitudinal studies | The diet is a protective factor to cognitive decline | 2020 | [58] |
| Nutritional formulas, fatty acid, ginseng, inositol, probiotics | systematic review: 32 randomized clinical trials | Interventions protect or delay the progression of cognitive decline | 2020 | [63] |
| Supplementation (vitamins B, vitamins E, omega-3 fatty acids, nutritional formulas) | systematic review and meta-analyses (PRISMA): 4 randomized clinical trials | No significant link between supplementation and cognitive function | 2020 | [65] |
| Traditional, healthy diet | systematic review and meta-analysis: 12 studies | Healthy diet reduces the risk of dementia | 2020 | [60] |
| Pro-inflammatory diet | systematic review and meta-analysis (PRISMA): 10 randomized clinical trials | Inflammatory diet is associated with cognitive decline | 2019 | [62] |
| Traditional, healthy diet and high-fat, high-glycemic diet | systematic reviews and meta-analyses (PRISMA): 26 studies | Healthy diet protects against the development of AD, unhealthy diet increases neurodegeneration | 2019 | [61] |

MCT, Medium Chain Triglyceride.
Future research on people with Alzheimer’s disease should focus on further evaluation of the impact of vitamin intake on cognitive performance in patients in order to be able to clearly define their effect and formulate international guidelines for diet and supplementation in patients with AD. In addition, they should explain the mechanisms that are not fully understood to be able to develop appropriate supplement formulations that would be easily distributed in the patient’s body.

To promote healthy aging, governments in many countries are introducing public health support programs. For example, the Universities of the Third Age are established that support the memory and cognitive abilities of the elderly. Older people, for economic reasons, do not use all the medications recommended for their specific conditions, therefore, programs are being introduced under which seniors receive some drugs for free (in Poland, it is the “Drugs75+” program). In addition, pharmaceutical care (including care for the elderly) is developing in Europe, the aim of which is to help senior citizens in proper pharmacotherapy: assessing whether the preparations and dietary supplements used do not interact, and whether the elderly person correctly uses, e.g., an inhaler or a glucometer (people with AD may have difficulty with this). Containers are sold in which the AD caregiver can distribute medications for the entire week. In addition, insufficient intake of vitamins may be related to the general malnutrition of the elderly. There are programs in Europe to prevent malnutrition in older people, this problem affects 13.5 to 29.7% of the elderly, including PROMISS (Prevention of Malnutrition In Senior Subjects in the EU) [74].

4. Conclusions

Research suggests that a diet rich in antioxidant vitamins may slow the progression of Alzheimer’s disease. Data on supplementation with vitamins A, B, C, D, and E vitamins are ambiguous. There are no international guidelines for dietary recommendations in AD. The conducted meta-analyses suggest that vitamins A, B, C, D, and E deficiencies may increase the risk of AD, therefore, a diet rich in vitamins A, D, C, B6, B12, and folic acid, as well as supplementation with higher doses (e.g., 2000 IE of vitamin E) seems to be recommended in the prevention of Alzheimer’s disease. Adequate quantities of fruit and vegetables will supplement the deficiency of antioxidant vitamins, which are often deficient in patients with dementia. Further research should focus on resolving unclear issues.

Author Contributions: Conceptualization, A.M., A.P.-J., R.M.-Ż., and K.S.; methodology, A.M. and A.P.-J.; writing—original draft preparation, A.M. and A.P.-J.; writing—review and editing, K.S. and R.M.-Ż.; visualization, A.M. and A.P.-J.; supervision, K.S. and R.M.-Ż.; project administration, K.S.; funding acquisition, K.S. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the Medical University of Białystok, grant number SUB/2/DN/20/003/2216.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Kalaria, R.N.; Maestre, G.E.; Arizaga, R.; Friedland, R.P.; Galasko, D.; Hall, K.; Luchsinger, J.A.; Ogunniyi, A.; Perry, E.K.; Potocnik, F.; et al. Alzheimer’s disease and vascular dementia in developing countries: Prevalence, management, and risk factors. Lancet Neurol. 2008, 7, 812–826. [CrossRef]
2. Gaweł, M.; Potulska-Chomik, A. Choroby neurodegeneracyjne: Choroba Alzheimera i Parkinsona [in Polish, Neurodegenerative diseases: Alzheimer’s and Parkinson’s disease]. Post. Nauk Med. 2015, 28, 468–475.
3. Alzheimer’s Association. 2014 Alzheimer’s disease facts and figures. Alzheimer Dement. 2014, 10, e47–e92. [CrossRef]
4. Bird, T.D. Alzheimer Disease Overview. 2018. Available online: https://www.ncbi.nlm.nih.gov/books/NBK1161/ (accessed on 14 February 2020).
5. Kim, Y.-J.; Kim, S.H.; Park, Y.; Park, J.; Lee, J.H.; Kim, B.C.; Song, W.K. miR-16-5p is upregulated by amyloid β deposition in Alzheimer’s disease models and induces neuronal cell apoptosis through direct targeting and suppression of BCL-2. Exp. Gerontol. 2020, 136, 110954. [CrossRef]
6. Cummings, J.L.; Isaacson, R.S.; Schmitt, F.A.; Velting, D.M. A practical algorithm for managing Alzheimer’s disease: What, when, and why? Ann. Clin. Transl. Neurol. 2015, 2, 307–323. [CrossRef]
1. Athanasopoulos, D.; Karagiannis, G.; Tsolaki, M. Recent Findings in Alzheimer Disease and Nutrition Focusing on Epigenetics. *Adv. Nutr.* **2016**, *7*, 917–927. [CrossRef]

2. Atri, A. The Alzheimer’s Disease Clinical Spectrum. *Med. Clin. N. Am.* **2019**, *103*, 263–293. [CrossRef]

3. Martyniuk-Gaca, A.; Papuć, E.; Tynecka-Turowska, M.; Rejdak, K. Choroba Alzheimera i jej rzadkie warianty oraz implikacje dla jakości życia. (In Polish: Alzheimer’s disease, its rare variants and implications for quality of life). *Dobrostan a Sian Zdrowia* **2016**, *10*, 127–138.

4. Brunton, L.L.; Lazo, J.S.; Parker, K.L.W. *Goodman and Gilman’s the Pharmacological*, 1st ed.; red. Polish edition Buczko; McGraw-Hill Professional Czelej: Lublin, Poland, 2007.

5. Talbot, K.; Wang, H.-Y.; Kazi, H.; Han, L.-Y.; Bakshi, K.P.; Stucky, A.; Fuino, R.L.; Kawaguchi, K.R.; Samoyedny, A.J.; Wilson, R.S.; et al. Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. *J. Clin. Investig.* **2012**, *122*, 1316–1338. [CrossRef]

6. Vinciguerra, F.; Graziano, M.; Hagnäs, M.; Frittitta, L.; Tumminia, A. Influence of the Mediterranean and Ketogenic Diets on Cognitive Status and Decline: A Narrative Review. *Nutrients* **2020**, *12*, 1019. [CrossRef]

7. Robinson, N.; Grabowski, P.; Rehman, I. Alzheimer’s disease pathogenesis: Is there a role for folate? *Mech. Ageing Dev.* **2018**, *174*, 86–94. [CrossRef] [PubMed]

8. Smith, P.J.; Blumenthal, J. Dietary Factors and Cognitive Decline. *J. Prev. Alzheimer Dis.* **2016**, *3*, 53–64.

9. Mohajeri, M.H.; Troesch, B.; Weber, P. Inadequate supply of vitamins and DHA in the elderly: Implications for brain aging and Alzheimer-type dementia. *Nutrients* **2015**, *31*, 261–275. [CrossRef] [PubMed]

10. De Jager, C.A.; Oulhaj, A.; Jacoby, R.; Refsum, H.; Smith, A.D. Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: A randomized controlled trial. *Int. J. Geriatr. Psychiatry* **2011**, *27*, 592–600. [CrossRef]

11. Chen, H.; Liu, S.; Ji, L.; Wu, T.; Ji, Y.; Zhou, Y.; Zheng, M.; Zhang, M.; Xu, W.; Huang, G. Folic Acid Supplementation Mitigates Alzheimer’s Disease by Reducing Inflammation: A Randomized Controlled Trial. *Mediat. Inflamm.* **2016**, *2016*, 1–10. [CrossRef]

12. Kwok, T.; Wu, Y.; Lee, I.; Lee, R.; Yung, C.Y.; Choi, G.; Lee, V.; Harrison, J.; Lam, L.C.W.; Mok, V.C.T. A randomized placebo-controlled trial of using B vitamins to prevent cognitive decline in older mild cognitive impairment patients. *Clin. Nutr.* **2020**, *39*, 2399–2405. [CrossRef]

13. Van der Zwaluw, N.L.; Dhonukshe-Rutten, R.A.M.; van Wijngaarden, J.P.; van de Rest, O.; Veld, P.H.I.T.; Enneman, A.W.; van Dijk, S.C.; Ham, A.C.; Swart, K.M.; et al. Results of 2-year vitamin B treatment on cognitive performance: Secondary data from an RCT. *Neurology* **2014**, *83*, 2158–2166. [CrossRef]

14. Oulhaj, A.; Jernerén, F.; Refsum, H.; Smith, A.D.; De Jager, C.A. Omega-3 Fatty Acid Status Enhances the Prevention of Cognitive Decline by B Vitamins in Mild Cognitive Impairment. *J. Alzheimer Dis.* **2016**, *50*, 547–557. [CrossRef]

15. Meng, H.; Li, Y.; Zhang, W.; Zhao, Y.; Niu, X.-Y.; Guo, J. The relationship between cognitive impairment and homocysteine in a B12 and folate deficient population in China. *Medicine* **2019**, *98*, e17970. [CrossRef]

16. Ulusu, N.N.; Yılmaz, G.; Erbayraktar, Z.; Evlice, A.T.; Aras, S.; Yener, G.; Avci, A. A Turkish 3-center study evaluation of serum folic acid and vitamin B12 levels in Alzheimer disease. *Clin. Nutr.* **2019**, *38*, e17970. [CrossRef]

17. An, Y.; Feng, L.; Zhang, X.; Wang, Y.; Wang, Y.; Tao, L.; Qin, Z.; Xiao, R. Dietary intakes and biomarker patterns of folate, vitamin B6, and vitamin B12 can be associated with cognitive impairment by hypermethylation of redox-related genes NUDT15 and TXNRD1. *Clin. Epigenetics* **2019**, *11*, 139. [CrossRef]

18. Jarosz, M. *Normy Żywności dla Populacji Polski*; Instytut Żywności i Żywienia: Warsaw, Poland, 2017. (In Polish: Nutrition standards for the Polish population)

19. Cosío-Planas, M.; Senserrick, J.; Arumi-Plana, M.; Alquézar, C.; Pallás, M.; Martín-Requero, Á.; Suñol, C.; Kaliman, P.; Sanfeliú, C. Role of Resveratrol and Selenium on Oxidative Stress and Expression of Antioxidant and Anti-Aging Genes in Immortalized Lymphocytes from Alzheimer’s Disease Patients. *Nutrients* **2019**, *11*, 1764. [CrossRef]

20. Eswaminathan, A.; Jicha, G.A. Nutrition and prevention of Alzheimer’s dementia. *Front. Aging Neurosci.* **2014**, *6*, 282. [CrossRef]
27. Da Silva, S.L.; Vellas, B.; Elemans, S.; Luchsinger, J.; Kamphuis, P.; Yaffe, K.; Sijben, J.W.C.; Groenendijk, M.; Stijnen, T. Plasma nutrient status of patients with Alzheimer’s disease: Systematic review and meta-analysis. *Alzheimer Dement.* 2013, 10, 485–502. [CrossRef]

28. Woloszynowska-Fraser, M.U.; Kouchmeshky, A.; McCaffery, P. Vitamin A and Retinoic Acid in Cognition and Cognitive Disease. *Annu. Rev. Nutr.* 2020, 40, 247–272. [CrossRef]

29. Sodhi, R.K.; Singh, N. Retinoids as potential targets for Alzheimer’s disease. *Pharmacol. Biochem. Behav.* 2014, 120, 117–123. [CrossRef]

30. Shahar, S.; Lee, L.K.; Rajab, N.; Lim, C.L.; Harun, N.A.; Noh, M.F.N.M.; Then, S.-M.; Jamal, R. Association Between Vitamin A, Vitamin E and Apolipoprotein E Status with Mild Cognitive Impairment among Elderly People in Low-Cost Residential Areas. *Nutr. Neurosci.* 2013, 16, 6–12. [CrossRef]

31. Yuan, C.; Fondell, E.; Ascherio, A.; Okereke, O.I.; Grodstein, F.; Hofman, A.; Willett, W.C. Long-Term Intake of Dietary Carotenoids Is Positively Associated with Late-Life Subjective Cognitive Function in a Prospective Study in US Women. *J. Nutr.* 2020, 150, 1871–1879. [CrossRef]

32. Péneau, S.; Galan, P.; Jeandel, C.; Ferry, M.; Andreeva, V.; Hercberg, S.; The SU.Vi.MAX 2 Research Group. Fruit and vegetable intake and cognitive function in the SU.VI.MAX 2 prospective study. *Am. J. Clin. Nutr.* 2011, 94, 1295–1303. [CrossRef]

33. Lane, M.A.; Bailey, S.J. Role of retinoid signalling in the adult brain. *Prog. Neurobiol.* 2005, 75, 275–293. [CrossRef]

34. Mecocci, P.; Polidori, M.C. Antioxidant clinical trials in mild cognitive impairment and Alzheimer’s disease. *Biochim. Biophys. Acta Mol. Basis Dis.* 2012, 1822, 631–638. [CrossRef]

35. Von Arnim, C.A.F.; Herbolsheimer, F.; Nikolaus, T.; Peter, R.; Biesalski, H.K.; Ludolph, A.C.; Riepe, M.; Simons, A.; The ActiFE Ulm Study Group. Dietary Antioxidants and Dementia in a Population-Based Case-Control Study among Older People in South Germany. *J. Alzheimer Dis.* 2012, 31, 717–724. [CrossRef]

36. Monacelli, F.; Acquarone, F.M.E.; Giannotti, C.; Borghi, R.; Nencioni, A. Vitamin C, Aging and Alzheimer’s Disease. *Nutrients* 2017, 9, 670. [CrossRef]

37. Choudhry, F.; Howlett, D.R.; Richardson, J.C.; Francis, P.T.; Williams, R.J. Pro-oxidant Diet Enhances β/γ Secretase-Mediated APP Processing in APP/PS1 Transgenic Mice. *Neurobiol. Aging* 2012, 33, 960–968. [CrossRef]

38. Dysken, M.W.; Sano, M.; Asthana, S.; Verretrees, J.E.; Pallaki, M.; Llorente, M.; Love, S.; Schellenberg, G.D.; McCarten, J.R.; Malphurs, J.; et al. Effect of Vitamin E and Memantine on Functional Decline in Alzheimer Disease. *JAMA* 2014, 311, 33–44. [CrossRef]

39. Kryscio, R.; Abner, E.L.; Caban-Holt, A.; Lovell, M.; Goodman, P.; Darke, A.K.; Yee, M.; Crowley, J.; Schmitt, F.A. Association of Antioxidant Supplement Use and Dementia in the Prevention of Alzheimer’s Disease by Vitamin E and Selenium Trial (PREADVIE). *JAMA Neurol.* 2017, 74, 567–573. [CrossRef]

40. Alavi Naeini, A.; Elmadfa, I.; Djazayery, A.; Barekatain, M.; Ghazvini, M.R.A.; Djalali, M.; Lederle, F.A.; Masaki, K.; et al. Tocopherol and Tocotrienol Plasma Levels Are Associated With Cognitive Performance of the Elderly With Mild Cognitive Impairment in Isfahan, Iran: A Double-Blind, Randomized, Placebo-Controlled Trial. *Eur. J. Nutr.* 2012, 51, 73–80. [CrossRef]

41. De Leeuw, F.A.; Honer, W.G.; Schneider, J.A.; Morris, M.C. Brain γ-Tocopherol Levels Are Associated with Presynaptic Protein Levels in Elderly Human Midfrontal Cortex. *J. Alzheimer Dis.* 2020, 77, 619–627. [CrossRef]

42. Mangialasche, F.; Xu, W.; Kivipelto, M.; Costanzi, E.; Ercolani, S.; Pigliautile, M.; Cecchetti, R.; Bagioni, M.; Simmons, A.; Soininen, H.; et al. Tocopherols and Tocotrienols Plasma Levels Are Associated With Cognitive Impairment. *Neurobiol. Aging* 2017, 33, 2282–2290. [CrossRef]

43. Agarwal, P.; Holland, T.M.; Wang, Y.; Holtzman, D.M.; Morris, M.C. Association of Strawberries and Anthocyanidin Intake with Alzheimer’s Dementia Risk. *Nutrients* 2019, 11, 3060. [CrossRef]

44. Bowman, G.L. Ascorbic Acid, Cognitive Function, and Alzheimer’s Disease: A Current Review and Future Direction. *BioFactors* 2012, 38, 114–122. [CrossRef]

45. Dursun, E.; Gezen-Ak, D. Vitamin D Basis of Alzheimer’s Disease: From Genetics to Biomarkers. *Hormones* 2018, 17, 7–15. [CrossRef]

46. Rossom, R.C.; Espeland, M.A.; Manson, J.E.; Dysken, M.W.; Johnson, K.C.; Lane, R.S.; Leblanc, E.S.; Leider, F.A.; Masaki, K.H.; Margolis, K.L. Calcium and Vitamin D Supplementation and Cognitive Impairment in the Women’s Health Initiative. *J. Am. Geriatr. Soc.* 2012, 60, 2197–2205. [CrossRef]
47. Shih, E.; Lee, W.; Hsu, J.; Wang, S.; Fuh, J.-L. Effect of vitamin D on cognitive function and white matter hyperintensity in patients with mild Alzheimer’s disease. *Geriatr. Gerontol. Int.* 2019, 20, 52–58. [CrossRef]

48. Aguilar-Navarro, S.G.; Mimenza-Alvarado, A.J.; Jiménez-Castillo, G.A.; Bracho-Vela, L.A.; Yeverino-Castro, S.G.; Ávila-Funes, J.A. Association of Vitamin D with Mild Cognitive Impairment and Alzheimer’s Dementia in Older Mexican Adults. *Rev. Investig. Clin.* 2019, 71, 381–386. [CrossRef]

49. Llewellyn, D.J. Vitamin D and Risk of Cognitive Decline in Elderly Persons. *Arch. Intern. Med.* 2010, 170, 1135–1141. [CrossRef]

50. Lee, D.H.; Chon, J.; Kim, Y.; Seo, Y.K.; Park, E.J.; Won, C.W.; Soh, Y. Association between vitamin D deficiency and cognitive function in the elderly Korean population. *Medicine 2020*, 99, e19293. [CrossRef]

51. Duchaine, C.S.; Talbot, D.; Nafti, M.; Giguère, Y.; Dodin, S.; Tourigny, A.; Carmichael, P.-H.; Laurin, D. Vitamin D status, cognitive decline and incident dementia: The Canadian Study of Health and Aging. *Can. J. Public Health* 2020, 111, 312–321. [CrossRef]

52. De Leeuw, F.A.; Van Der Flier, W.M.; Tijms, B.M.; Scheltens, P.; Mendes, V.M.; Manadas, B.; Bierau, J.; Van Wijk, N.; Heuvel, E.G.V.; Mohajeri, M.H.; et al. Specific Nutritional Biomarker Profiles in Mild Cognitive Impairment and Subjective Cognitive Decline Are Associated with Clinical Progression: The NUDAD Project. *J. Am. Med. Dir. Assoc.* 2020, 21, 1513.e1–1513.e17. [CrossRef]

53. Annweiler, C. Vitamin D in dementia prevention. *Am. N. Y. Acad. Sci.* 2016, 1367, 57–63. [CrossRef]

54. Annweiler, C.; Fantino, B.; Parot-Schinkel, E.; Thiery, S.; Gautier, J.; Beauchet, O. Alzheimer’s disease input and cognitive function in the elderly Korean population. *Medicine* 2020; 111, 1513.e1–1513.e17. [CrossRef]

55. Limongi, F.; Siviero, P.; Bozanic, A.; Noale, M.; Veronese, N.; Maggi, S. The Effect of Adherence to the Mediterranean Diet on Late-Life Cognitive Disorders: A Systematic Review. *J. Am. Med. Dir. Assoc.* 2020, 21, 1402–1409. [CrossRef]

56. Shen, L.; Ji, H.-F. Associations between Homocysteine, Folic Acid, Vitamin B12 and Alzheimer’s Disease: Insights from Meta-Analyses. *J. Alzheimers Dis.* 2015, 46, 777–790. [CrossRef]

57. Zhang, H.; Hardie, L.J.; Bawajeeh, A.O.; Cade, J. Meat Consumption, Cognitive Function and Disorders: A Systematic Review with Narrative Synthesis and Meta-Analysis. *Nutrients 2020*, 12, 1528. [CrossRef]

58. Przybelski, R.; Agrawal, S.; Krueger, D.; Engelke, J.A.; Walbrun, F.; Binkley, N. Rapid correction of low vitamin D status in nursing home residents. *Osteoporos. Int.* 2008, 19, 1621–1628. [CrossRef]

59. Liu, Y.H.; Gao, X.; Na, M.; Kris-Etherton, P.; Mitchell, D.C.; Jensen, G.L. Dietary pattern, diet quality, and cognitive function in the elderly Korean population. *Arch. Intern. Med.* 2019, 71, 381–386. [CrossRef]

60. Samadi, M.; Moradi, S.; Moradinazar, M.; Mostafai, R.; Pasdar, Y. Dietary pattern in relation to the risk of Alzheimer’s disease: A systematic review. *Neural. Sci.* 2019, 40, 2031–2043. [CrossRef]

61. Moreira, S.C.; Jansen, A.K.; Silva, F.M. Dietary interventions and cognition of Alzheimer’s disease patients: A systematic review of randomized controlled trials. *Dement. Neuropsychol.* 2019, 41, 109–120. [CrossRef]

62. Haider, S.; Schwarzinger, A.; Stefanac, S.; Soysal, P.; Smith, L.; Veronese, N.; Dorner, T.E.; Grabovac, I. Nutrient supplements for neuropsychiatric symptoms in people with dementia: A systematic review and meta-analysis. *Int. J. Geriatri. Psychiatry* 2020, 35, 1285–1291. [CrossRef]

63. Zhang, C.; Luo, J.; Yuan, C.; Ding, D. Vitamin B12, B6, or folate and cognitive function in community-dwelling older adults: A systematic review and meta-analysis. *J. Alzheimer Dis.* 2020, 27, 791–794. [CrossRef]

64. Clarke, R.; Bennett, D.; parish, S.; Lewington, S.; Skeaff, M.; Eussen, S.J.P.; Lewerin, C.; Stott, D.J.; Armitage, J.; Hankey, G.J.; et al. Effects of homocysteine lowering with B vitamins on cognitive aging: Meta-analysis of 11 trials with cognitive data on 22,000 individuals. *Am. J. Clin. Nutr.* 2014, 100, 657–666. [CrossRef]
68. Li, F.-J.; Shen, L.; Ji, H.-F. Dietary Intakes of Vitamin E, Vitamin C, and β-Carotene and Risk of Alzheimer’s Disease: A Meta-Analysis. *J. Alzheimer Dis.* 2012, 31, 253–258. [CrossRef]

69. Chai, B.; Gao, F.; Wu, R.; Dong, T.; Gu, C.; Lin, Q.; Zhang, Y. Vitamin D deficiency as a risk factor for dementia and Alzheimer’s disease: An updated meta-analysis. *BMC Neurol.* 2019, 19, 284. [CrossRef]

70. Yang, K.; Chen, J.; Li, X.; Zhou, Y. Vitamin D concentration and risk of Alzheimer disease. *Medicine* 2019, 98, e16804. [CrossRef]

71. Jayedi, A.; Rashidy-Pour, A.; Shab-Bidar, S. Vitamin D status and risk of dementia and Alzheimer’s disease: A meta-analysis of dose-response. *Nutr. Neurosci.* 2018, 22, 750–759. [CrossRef]

72. Ashley, S.; Bradburn, S.; Murgatroyd, C. A meta-analysis of peripheral tocopherol levels in age-related cognitive decline and Alzheimer’s disease. *Nutr. Neurosci.* 2019, 1–15. [CrossRef]

73. Dong, Y.; Chen, X.; Liu, Y.; Shu, Y.; Chen, T.; Xu, L.; Li, M.; Guan, X. Do low-serum vitamin E levels increase the risk of Alzheimer disease in older people? Evidence from a meta-analysis of case-control studies. *Int. J. Geriatr. Psychiatry* 2017, 33, e257–e263. [CrossRef]

74. PROMISS Nutrients for Healthy Ageing. Available online: www.promiss-vu.eu (accessed on 7 November 2020).

**Publisher’s Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.